The Scientific Advisory Board (SAB) plays a vital role by assessing the progress of individual projects, helping to prioritize lead development drug candidates, and evaluating gating metrics for progression. The SAB also provides guidance to the scientific cores to ensure that they function efficiently to deliver high-quality support for compound progression.
Emilio A Emini, Ph.D., FCPP, FAAM
Chief Executive Officer
Bill and Melinda Gates Medical Research Institute
Zhu Hong, Ph.D.
Executive Director, Chairman of the Board and CEO
Brii Biosciences
Joseph P. Vacca, Ph.D.
J. Vacca Consulting
Arturo Casadevall, MD, Ph.D.
Professor of Medicine
Johns Hopkins School of Medicine
Susan R. Weiss, Ph.D.
Professor of Microbiology
University of Pennsylvania
Richard R. Kuhn, Ph.D.
Professor of Biological Sciences
Purdue University
George Drusano, M.D.
Director, Institute for Therapeutic Innovation
University of Florida
Specialty Name
Specialty Name
We use cookies to improve your site experience. By using this site,
you agree to our Terms & Conditions. Also, please read our Privacy Policy. Accept All CookiesLearn More